logo
Plus   Neg
Share
Email

Novartis : Kisqali Prolongs Life In Women With HR+/HER2- Advanced Breast Cancer

Novartis (NVS) said that Kisqali significantly prolongs life in women with hormone-receptor positive, human epidermal growth factor receptor-2 negative or HR+/HER2- advanced breast cancer now in two distinct late-stage trials.

"We are thrilled that Kisqali combination therapy again has demonstrated improved overall survival for patients with HR+/HER2- advanced breast cancer - first in pre-menopausal and peri-menopausal women in MONALEESA-7, and now in post-menopausal women in MONALEESA-3," said Susanne Schaffert, PhD, President, Novartis Oncology.

According to the company, no new safety signals were observed; adverse events were consistent with previously reported Phase III trial results. Kisqali is approved for use in various indications in more than 75 countries around the world.

For comments and feedback contact: editorial@rttnews.com

Follow RTT
>